Physician profile
Farid M Dharamsi
NPI 1619107828
$159,328.14
in general payments reported to CMS, 2019-2025
19 companies · $47K in 2025
The $47K reported for 2025 was more than what 99% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $374 · 2021: $218 · 2022: $12K · 2023: $48K · 2024: $51K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $131K · Travel and Lodging: $8,608 · Food and Beverage: $6,508 · Education: $19.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $131,136.00 |
| Travel and Lodging | $8,608.14 |
| Food and Beverage | $6,508.34 |
| Education | $19.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $145,570.72 | 2019-2025 | Botox, Kybella |
| Allergan, INC. | $11,911.23 | 2019-2022 | |
| Leo Pharma INC. | $330.25 | 2024-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $265.62 | 2020-2025 | Absorica Ld, Winlevi |
| Galderma Laboratories, L.P. | $263.93 | 2024-2025 | Dysport, Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $234.32 | 2019-2025 | Siliq |
| Merz North America, INC. | $159.04 | 2019-2024 | |
| Lilly USA, LLC | $129.71 | 2019-2025 | Taltz, Ebglyss |
| Incyte Corporation | $92.42 | 2022-2024 | Opzelura |
| Celgene Corporation | $74.83 | 2019 | |
| Journey Medical Corporation | $74.45 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $53.96 | 2020 | |
| Janssen Biotech, INC. | $39.45 | 2023-2024 | Tremfya |
| Almirall LLC | $38.09 | 2023-2025 | Seysara |
| Amgen INC. | $21.76 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $19.43 | 2019 | |
| Biofrontera INC. | $17.41 | 2019 | |
| Mimedx Group, INC. | $17.20 | 2024 | |
| Dermira, INC. | $14.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farid Dharamsi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.